Professional Documents
Culture Documents
Author
Victoria Hendrick, MD
All topics are updated as new evidence becomes available and our peer review
process is complete.
Literature review current through: Oct 2014. | This topic last updated: Jul 24,
2014.
INTRODUCTION Medications are commonly used to treat pregnant patients,
including those with manic and hypomanic episodes [1]. At least one prescription
drug is taken by more than 60 percent of pregnant patients [2], and psychotropic
drugs are taken by 21 to 33 percent [3,4].
This topic discusses pharmacotherapy for pregnant patients with mania or
hypomania. Treatment of bipolar major depression during pregnancy, prenatal
maintenance pharmacotherapy for bipolar disorder, the teratogenic and postnatal
risks of medications used for bipolar disorder, and the general treatment of mania
and hypomania is discussed separately.
DEFINITION OF BIPOLAR DISORDER Bipolar disorder is characterized by
episodes of mania (table 1), hypomania (table 2), and major depression (table 3)
[5]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with
bipolar I disorder experience manic episodes, and nearly always experience major
depressive and hypomanic episodes. Bipolar II disorder is marked by at least one
hypomanic episode, at least one major depressive episode, and the absence of
manic episodes. Additional information about the clinical features and diagnosis of
bipolar disorder is discussed separately. (See "Bipolar disorder in adults: Clinical
features" and "Bipolar disorder in adults: Assessment and diagnosis".)
INDICATIONS Pharmacotherapy is indicated for pregnant patients with manic
and hypomanic episodes that are characterized by [6]:
Suicidal or homicidal ideation or behavior
Aggressive behavior
Psychotic features (delusions or hallucinations)
Poor judgement that places the patient or others at imminent risk of being harmed
Moderate to severe impairment of social or occupational functioning
Involvement in pleasurable activities that have a high potential for painful
consequences (eg, unrestrained buying sprees or sexual indiscretions)
Medications may not be indicated for some episodes of hypomania. However, it is
not clear which untreated hypomanic episodes will progress to mania that requires
pharmacotherapy.
MANAGEMENT
General principles Bipolar mood episodes during pregnancy are usually
treated by perinatal or general psychiatrists in collaboration with obstetricians and
Outpatient treatment may be suitable for patients with less acute symptoms (eg,
thoughts that family members would be better off if the patient was dead, with no
plan or intent to commit suicide)
Monitoring the patient The psychiatric status of pregnant bipolar patients
should be regularly monitored, with particular attention to suicidal ideation and
psychosis [7,23]. Patients taking medications are also assessed for therapeutic
and adverse effects. In addition, serum concentrations of medications with
established therapeutic levels (eg, lithium) should be checked. Monitoring pregnant
patients who take lithium is discussed separately. (See "Bipolar disorder in women:
Preconception and prenatal maintenance pharmacotherapy", section on
'Refractory patients'.)
The frequency of assessing pregnant bipolar patients generally ranges from daily
to monthly, depending upon the type and severity of symptoms. Hospitalized
patients are monitored daily, and patients with active suicidal ideation, a specific
plan, and intent to kill themselves typically require constant observation.
Outpatients who have not achieved substantial improvement in the number,
intensity, and frequency of symptoms are generally seen weekly; patients who
have improved substantially may be seen every two to four weeks until they remit.
Duration of individual drug trial We suggest treating pregnant patients with
mania and hypomania for three weeks before determining whether a specific drug
is beneficial, based upon the duration of most randomized trials (which excluded
pregnant patients) [11]. Response is defined as stabilizing the patients safety and
substantial improvement in the number, intensity, and frequency of symptoms.
SPECIFIC TREATMENTS Despite clinical differences between mania and
hypomania (eg, hypomania is less severe than mania), for the purpose of
treatment these mood elevated syndromes are considered to be similar and thus
treated with the same medications [15,21,22].
First line medications For manic and hypomanic pregnant patients, we
suggest first-generation antipsychotics, which have been widely used during
pregnancy [4,24]. We prefer haloperidol, based upon its demonstrated efficacy in
randomized trials (which excluded pregnant patients) [11], and other studies that
suggest haloperidol is not associated with an increased risk of congenital
anomalies [3,25]. Using haloperidol is consistent with practice guidelines from the
United Kingdom National Institute for Health and Clinical Excellence [23,26], and
haloperidol is preferred by many authorities [1,18,27]. Other first-generation
antipsychotics that are reasonable alternatives to haloperidol include
chlorpromazine, fluphenazine, perphenazine, thiothixene, and trifluoperazine [28].
Clinicians can expect that response to a first-generation antipsychotic will occur in
approximately 50 percent of patients, based upon trials in nonpregnant patients
[29].
therapy (ECT) [40]. For patients unresponsive to sequential trials of lithium and
ECT, other options include lithium plus an antipsychotic, carbamazepine, and
valproate.
Lithium For pregnant patients with manic episodes that do not respond to
multiple antipsychotics, we suggest lithium, based upon its efficacy and side effects
in randomized trials (which excluded pregnant patients) [11]. Although lithium is
generally regarded as teratogenic due to increased risks of cardiac defects (eg,
Ebsteins anomaly) [35-37], many authorities consider the absolute risk small
[1,4,17,32,41]. Clinicians can expect that up to approximately 50 percent of
patients will respond, based upon trials in nonpregnant patients [29].
The dose schedule for lithium, use of serum concentrations to establish the proper
dose, and lithium toxicity are discussed separately, as are using lithium during
pregnancy and lithiums reproductive safety profile. (See "Bipolar disorder in adults
and lithium: Pharmacology, administration, and side effects" and "Bipolar disorder
in women: Preconception and prenatal maintenance pharmacotherapy", section on
'Refractory patients' and "Teratogenic and postnatal risks of antipsychotics,
benzodiazepines, lithium, and electroconvulsive therapy", section on 'Lithium'.)
Electroconvulsive therapy For pregnant patients with moderate to severe
manic episodes that do not respond to sequential trials of antipsychotics and
lithium, we suggest electroconvulsive therapy (ECT), which is generally regarded
as efficacious and safe [42,43]. The use of ECT for pregnant bipolar patients is
consistent with recommendations in multiple practice guidelines [7,26,44-46].
Evidence for the efficacy of ECT includes studies that found ECT is effective for
mania in patients who are not pregnant. (See "Bipolar disorder in adults:
Indications for and efficacy of electroconvulsive therapy (ECT)", section on
'Mania'.)
In addition, a review of observational studies of pregnant patients treated for mood
or psychotic disorders with ECT found that among 68 cases with outcome data, at
least partial remission occurred in 78 percent [47]. Among the seven patients with
bipolar disorder, remission occurred in five and partial remission in one.
ECT during pregnancy is generally regarded as safe for the mother and fetus
[43,48,49]. Many authorities think that ECT poses fewer risks than untreated
bipolar mood episodes and medications that are potentially teratogenic (eg,
valproate and carbamazepine, and to a lesser extent lithium) [1,43,47,50,51]. The
reproductive safety profile of ECT is discussed separately. (See "Teratogenic and
postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive
therapy", section on 'Electroconvulsive therapy'.)
ECT is typically well tolerated and there are no absolute contraindications to ECT,
even among patients whose general medical status is compromised [43]. However,
safety concerns regarding ECT necessitate preprocedure obstetric consultation
(consistent with guideline recommendation), with emphasis upon assessing risk
factors for spontaneous abortion, preterm labor, abruption, and uteroplacental
or more. A review of prenatal ECT found that the mean number of treatments per
ECT course was 11 [47]. The number and frequency of treatments in the general
use of ECT is discussed separately, as are the adjustments in ECT technique for
pregnant patients. (See "Overview of electroconvulsive therapy (ECT) for adults",
section on 'Treatment course' and "Technique for performing electroconvulsive
therapy (ECT) in adults", section on 'Pregnancy'.)
Following a course of ECT, clinicians usually prescribe maintenance
pharmacotherapy. (See "Bipolar disorder in women: Preconception and prenatal
maintenance pharmacotherapy", section on 'Specific drugs'.)
Other options For pregnant bipolar patients with moderate to severe manic
episodes that do not respond to sequential trials of antipsychotics, lithium, and
ECT, we suggest in order of preference:
Lithium plus an antipsychotic For patients who do not respond to lithium
monotherapy and decline or do not have access to ECT, we suggest adding either
a first or second-generation antipsychotic to lithium, based upon randomized trials
that excluded pregnant patients. (Response is defined as stabilizing the safety of
the patient, as well as substantial improvement in the number, intensity, and
frequency of symptoms.) For patients who do not respond to antipsychotics,
lithium, and ECT, we concurrently start lithium plus an antipsychotic. No head-tohead trials have compared medication combinations consisting of lithium plus an
antipsychotic; we typically use lithium plus haloperidol, risperidone, quetiapine, or
olanzapine. The choice of an antipsychotic is based upon factors including past
response to medications, side effect profiles, comorbid general medical conditions,
potential for drug-drug interactions, patient preference, and cost. As an example, if
the patient previously showed a modest response to haloperidol and no response
to risperidone, quetiapine, or olanzapine, we would choose lithium plus haloperidol.
The efficacy of lithium plus an antipsychotic in randomized trials (that excluded
pregnant patients) is discussed separately, as are the doses, side effects,
pharmacology, and reproductive safety profiles. (See "Bipolar disorder in adults:
Pharmacotherapy for acute mania and hypomania" and "Second-generation
antipsychotic medications: Pharmacology, administration, and comparative side
effects", section on 'Individual medications' and "Teratogenic and postnatal risks of
antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy".)Specific
medication interactions that can occur may be determined using the drug
interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be
accessed from the UpToDate online search page or through the individual drug
information topics in the section on Drug interactions.Refractory patients who do
not respond to or tolerate one lithium/antipsychotic combination should be treated
with a second combination. We usually taper and discontinue the failed
antipsychotic at the same time that a different antipsychotic is started and titrated
up. The failed antipsychotic is generally tapered over one to two weeks by the
same amount for each dose decrease (eg, haloperidol 8 mg per day is decreased
by 2 mg per day, every one to three days).
1.
2.
3.
4.
5.
6.
7.
8.
9.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
Victoria Hendrick, MD
Literature review current through: Oct 2014. | This topic last updated: Apr 16,
2014.
INTRODUCTION Medications are commonly used to treat pregnant patients,
including those with bipolar major depression [1]. At least one prescription drug is
taken by more than 60 percent of pregnant patients [2], and psychotropic drugs are
taken by 21 to 33 percent [3,4].
This topic discusses treatment of pregnant patients with bipolar major depression.
Treatment of manic and hypomanic episodes during pregnancy, prenatal
maintenance pharmacotherapy for bipolar disorder, the teratogenic and postnatal
risks of pharmacotherapy for bipolar disorder, and the general treatment of bipolar
major depression are discussed separately.
DEFINITION OF BIPOLAR DISORDER Bipolar disorder is characterized by
episodes of mania (table 1), hypomania (table 2), and major depression (table 3)
[5]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with
bipolar I disorder experience manic episodes, and nearly always experience major
depressive and hypomanic episodes. Bipolar II disorder is marked by at least one
hypomanic episode, at least one major depressive episode, and the absence of
manic episodes. Additional information about the clinical features and diagnosis of
bipolar disorder is discussed separately. (See "Bipolar disorder in adults: Clinical
features" and "Bipolar disorder in adults: Assessment and diagnosis", section on
'Diagnosis'.)
INDICATIONS Pharmacotherapy is indicated for pregnant patients with bipolar
major depression that is characterized by [6]:
Suicidal or homicidal ideation or behavior
Aggressive behavior
Psychotic features (delusions or hallucinations)
Poor judgement that places the patient or others at imminent risk of being harmed
Moderate to severe impairment of social or occupational functioning
GENERAL PRINCIPLES AND MANAGEMENT Bipolar mood episodes during
pregnancy are usually treated by perinatal or general psychiatrists in collaboration
with obstetricians and primary care clinicians [4,7-10].
For pregnant patients with bipolar major depression, treatment is based upon
randomized trials that excluded pregnant patients [11-14], as well as observational
studies, birth registries, and clinical experience [15].
Additional information about the general principles and management of treating
bipolar mood episodes during pregnancy are discussed separately, as is the
general treatment of bipolar major depression. (See "Bipolar disorder in pregnant
women: Treatment of mania and hypomania", section on 'Management' and
"Bipolar disorder in adults: Pharmacotherapy for acute depression".)
started and titrated up. Lamotrigine is usually tapered by the same amount for each
dose decrease over a one to two week period. As an example, lamotrigine 200 mg
per day is decreased by 50 mg per day every three to four days.
Second-generation antipsychotics may cause metabolic complications (eg,
hyperglycemia and obesity) that are associated with risks to the mother and fetus
[27,28]. These risks are discussed separately, as are monitoring of metabolic
parameters in pregnant patients taking second-generation antipsychotics and the
efficacy, dose, reproductive safety, pharmacology, and side effects of quetiapine.
(See "Bipolar disorder in women: Preconception and prenatal maintenance
pharmacotherapy", section on 'Metabolic complications' and "Bipolar disorder in
adults: Pharmacotherapy for acute depression" and "Teratogenic and postnatal
risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy",
section on 'Second-generation' and "Second-generation antipsychotic medications:
Pharmacology, administration, and comparative side effects", section on
'Quetiapine'.)
Refractory patients Pregnant patients with bipolar major depression often do
not respond to sequential trials of lamotrigine and quetiapine. For these refractory
patients, we suggest tapering and discontinuing quetiapine over one to two weeks
at the same time that another medication regimen is started and titrated up.
(Response is defined as stabilizing the safety of the patient and others, as well as
substantial improvement in the number, intensity, and frequency of symptoms.)
Quetiapine is generally tapered by the same amount for each dose decrease. As
an example, quetiapine 600 mg per day is decreased by 50 to 100 mg per day,
every one to two days.
We suggest using the following treatments in sequence for pregnant patients with
refractory bipolar major depression, based upon their efficacy in randomized trials
(which excluded pregnant patients), reproductive safety profiles, and adverse
effects. Although the benefit of fluoxetine plus olanzapine and the combination of
lamotrigine and lithium appear to be comparable, neither fluoxetine nor olanzapine
appear to be associated with teratogenic effects. By contrast, lithium is generally
regarded as teratogenic [29-31]. The proportion of patients who respond to any of
the following treatment regimens may be as high as approximately 50 percent,
based upon trials in nonpregnant patients [11,12].
Fluoxetine plus olanzapine Fluoxetine plus olanzapine is efficacious for bipolar
major depression in nonpregnant patients [12,32]. However, second-generation
antipsychotics, especially olanzapine, may cause metabolic complications (eg,
hyperglycemia and obesity) that are associated with risks to the mother and fetus
[27,28]. These risks are discussed separately, as are monitoring of metabolic
parameters in pregnant patients taking second-generation antipsychotics and the
efficacy, dose, reproductive safety, pharmacology, and side effects of fluoxetine
and olanzapine. (See "Bipolar disorder in women: Preconception and prenatal
maintenance pharmacotherapy", section on 'Metabolic complications' and
"Teratogenic and postnatal risks of antipsychotics, benzodiazepines, lithium, and
electroconvulsive therapy" and "Selective serotonin reuptake inhibitors:
pregnant [35,36]; ECT is thus recommended by several practice guidelines [7,3740]. The efficacy, adverse maternal and fetal effects, and reproductive safety of
ECT are discussed separately, as is the technique for performing ECT during
pregnancy. (See "Bipolar disorder in adults: Indications for and efficacy of
electroconvulsive therapy (ECT)", section on 'Bipolar major depression' and
"Bipolar disorder in pregnant women: Treatment of mania and hypomania", section
on 'Electroconvulsive therapy' and "Teratogenic and postnatal risks of
antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section
on 'Electroconvulsive therapy' and "Technique for performing electroconvulsive
therapy (ECT) in adults", section on 'Pregnancy'.)
ADJUNCTIVE TREATMENT
Psychotherapy For pregnant patients with bipolar major depression who are
treated with pharmacotherapy, we suggest adjunctive psychotherapy based upon
randomized trials in nonpregnant patients [2,6,41]. As an example, a one-year
randomized trial compared intensive psychotherapy plus pharmacotherapy with
brief psychoeducation plus pharmacotherapy in 293 nonpregnant patients with
bipolar major depression [42]. Intensive psychotherapy consisted of family therapy,
cognitive-behavioral therapy, or interpersonal and social rhythm therapy, with up to
30 sessions (50 minutes each) administered over nine months; brief
psychoeducation included three 50-minute sessions instructing patients about the
clinical features and treatment of bipolar disorder. Recovery occurred in more
patients who received adjunctive intensive psychotherapy compared with brief
psychoeducation (64 versus 52 percent), and outcome did not differ significantly
among the three intensive therapies. Using psychotherapy is also supported by
randomized trials in pregnant patients with unipolar major depression [43], and is
consistent with treatment guidelines [26].
Omega-3 fatty acids For pregnant patients with bipolar major depression,
dietary supplementation with omega-3 fatty acids (eg, eicosapentaenoic acid 1 to 2
grams per day) as adjunctive treatment is reasonable, based upon limited evidence
in meta-analyses of randomized trials (which excluded pregnant patients) [44,45]
and the apparent lack of serious side effects. In addition, prenatal intake of omega3 fatty acid supplements may have modest beneficial effects on fetal
neurodevelopment, and do not have known harmful effects. The efficacy of omega3 fatty acids and the risks and benefits during pregnancy are discussed separately.
(See "Bipolar disorder in adults: Pharmacotherapy for acute depression" and "Fish
consumption during pregnancy".)
RESIDUAL INSOMNIA Bipolar major depression in pregnant patients often
includes insomnia, which may persist despite resolution of the depressive
syndrome. For patients with residual insomnia, we suggest behavioral therapy,
including education about sleep hygiene (table 6) and stimulus control (table 7).
Patients unresponsive to behavior therapy typically receive additional treatment
with low dose doxepin. Treatment of insomnia is discussed separately. (See
"Treatment of insomnia".)
55.
56.
57.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
98.